Children and teenagers could benefit from new asthma therapy

Children aged 6-17 could benefit from tiotropium Respimat if the drug is added to maintenance asthma therapy, according to findings from a Phase 3 clinical trial. The findings, presented at the European Respiratory Society’s (ERS) 2016’s annual conference, were taken from the Phase 3 CanoTinA-asthma trail by pharma Boehringer Ingelheim. The study found that by adding tiotropium Respimat to maintenance therapy lung function was significantly improved when compared to placebo. The trial investigated tiotropium Respimat as an add-on therapy for children who were already taking an inhaled corticosteroid (ICS), or an ICS combined with other maintenance therapy. In the study,